Sign up Australia
Proactive Investors - Run By Investors For Investors

Invion teams with Hudson Institute to advance light-based cancer therapy research

Initial projects will focus on ovarian cancer and will expand into other cancer indications.
cancer cells
Light-based therapy to kill cancer cells

Invion Ltd (ASX:IVX) has signed a research and development (R&D) agreement with leading Australian medical research institute, Hudson Institute of Medical Research.

The agreement provides a framework for Invion and Hudson Institute to collaborate on R&D projects based on Invion’s Photosoft technology for the treatment of cancers.

Light-based therapy to kill cancer cells

Invion is developing Photosoft as a next generation photo dynamic therapy (PDT).

PDT uses non-toxic photosensitisers and visible light in combination with oxygen to kill malignant cells, shut down tumours and to stimulate the immune system.

In contrast to surgery, radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation and invasion of a tumour by leukocytes.

Targeting circulating cancer cells and deeply seated tumours

Photosoft is targeted to address the limitations of first-generation PDT therapies through better solubility and stronger absorption that allows deeper penetration of tissues and better tumour specificity.

Invion’s Photosoft uses a laser light activation method based on short, pulsating ‘near infrared’ (NIR) wavelengths.

It is hypothesised that NIR light therapy allows more effective whole-of-body systemic treatment that can target circulating cancer cells as well as deeply seated tumours.

Initial projects to focus on ovarian cancer

Under the new agreement, Hudson Institute will provide the research facilities and expertise required to undertake individual Invion-sponsored research projects.

Furthermore, Hudson Institute will be responsible for all legislative and professional standards compliance requirements, in accordance with global best practice.

Initial projects will focus on ovarian cancer, and it is envisioned that projects will quickly expand into other cancer indications.

READ: Invion's strategic alliance with Cho Group provides distribution opportunities

Invion has an agreement with The Cho Group to conduct clinical development of Photosoft globally.

The Cho Group will provide non-dilutive funding to Invion for R&D and clinical trials as part of a global development strategy for the asset.

View full IVX profile View Profile

Invion Ltd Timeline

Newswire
September 01 2015
Newswire
August 28 2015
Newswire
March 12 2015

Related Articles

pipette and petri dish
June 20 2018
As well as developing its lead compound, Silence has also been busy taking its larger rivals to court over alleged patent infringements
Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use